Anzeige
Mehr »
Login
Sonntag, 29.09.2024 Börsentäglich über 12.000 News von 691 internationalen Medien
Von 0,059 € auf 0,26 €: Die Gold-Aktie, die alle Erwartungen übertrifft
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
320 Leser
Artikel bewerten:
(1)

Alpine 4 Technologies, Ltd.: Alpine 4 Holdings, Inc. Subsidiary, VAYU (US), Inc. Welcomes Recently Retired U.S Airforce C-sUAS/sUAS Director of Programs/Nuclear Convoy, Technical Sergeant Nathan Grier, to the Team

PHOENIX, AZ / ACCESSWIRE / March 18, 2021 / Alpine 4 Holdings, Inc. (OTCQB:ALPP), a leading operator and owner of small market businesses welcomes recently retired U.S Airforce Technical Sergeant, Nathan Grier, to the Vayu (US), Inc. (Vayu) team. Mr. Grier is the former Programs Director of Counter Small Unmanned Aerial Systems (C-sUAS)/ Small Unmanned Aerial Systems (sUAS)/ Nuclear Convoy for the U.S. Airforce.

Mr. Grier was responsible for establishing the F.E. Warren Airforce Bases' UAVs lab where he maintained the Research Development Test & Evaluation (RDT&E) Program for C-sUAS and sUAS technology projects. The RDT&E Program provides physical security equipment and analyses to meet the immediate and projected force protection challenges of the Services and the combatant commands (COCOMs). Mr. Grier is the Air Force Global Strike subject matter expert on all sUAS and C-sUAS matters, training all new pilots to fly sUAS, obtaining FAA Part 107 certifications and creating and authoring C-sUAS doctrine/literature used by all U.S. Nuclear Intercontinental Ballistic Missile Wings.

Technical Sergeant Grier is said to be the most well-known sUAS and C-sUAS expert in the Security Forces Community. His knowledge and technical expertise had impressed General officers who toured his sUAS/C-sUAS laboratory at FE Warren AFB. Colleagues were proud to have him represent the Security Forces community and advancing the capabilities to defend and defeat threats to military resources.

Additionally, Mr. Grier has a background as a Cyber Security Manager with the 18th Military Police (MP) Brigade, as he himself was an MP. He anticipates completing his master's degree in cyber security in June of this year.

Daniel Pepper, CEO of Vayu, had this to say, "We are immensely excited for this opportunity to work with Nathan Grier. He brings an unparalleled range of UAS leadership experience to our team and will help us grow in important and strategic ways."

Kent Wilson, CEO of Alpine 4, the parent company of Vayu, had this to say, "Nathan adds a valuable and unique facet to the Vayu talent offering. His background as a U.S. Airforce Sergeant adds an invaluable depth of experience to the A4 Aerospace family of companies when representing Alpine 4 before our US Military customers. In addition, he has experience as a trained flight officer and pilot of the Impossible Aerospace US-1 drone and was actively involved in bringing the US-1 to the U.S. Airforce. We are elated to have Nathan and his talents within the Alpine 4 family!"

About Alpine 4 Holdings: Alpine 4 Holdings, Inc. (ALPP) is a publicly traded conglomerate that is acquires businesses that fit into its disruptive DSF business model of Drivers, Stabilizers, and Facilitators. At Alpine 4, we understand the nature of how technology and innovation can accentuate a business. Our focus is on how the adaptation of new technologies, even in brick-and-mortar businesses, can drive innovation. We also believe that our holdings should benefit synergistically from each other, have the ability to have collaborate across varying industries, spawn new ideas and create fertile ground for competitive advantages.

Four principles at the core of our business are Synergy. Innovation. Drive. Excellence. At Alpine 4, we believe synergistic innovation drives excellence. By anchoring these words to our combined experience and capabilities, we can aggressively pursue opportunities within and across vertical markets. We deliver solutions that not only drive industry standards, but also increase value for our shareholders.

Contact:
Investor Relations
investorrelations@alpine4.com
www.alpine4.com

Forward-Looking Statements: The information disclosed in this press release is made as of the date hereof and reflects Alpine 4 most current assessment of its historical financial performance. Actual financial results filed with the SEC may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors the Company identifies from time to time in its filings with the SEC. Although Alpine 4 believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Alpine 4 disclaims any intention or obligation to update the forward-looking statements for subsequent events.

SOURCE: Alpine 4 Technologies, Ltd.



View source version on accesswire.com:
https://www.accesswire.com/636208/Alpine-4-Holdings-Inc-Subsidiary-VAYU-US-Inc-Welcomes-Recently-Retired-US-Airforce-C-sUASsUAS-Director-of-ProgramsNuclear-Convoy-Technical-Sergeant-Nathan-Grier-to-the-Team

© 2021 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.